… of direct oral anticoagulants, particularly in countries where they are currently not widely used
because of cost. Direct oral anticoagulants … the pharmacology of direct oral anticoagulants, …

… now have oral anticoagulants with a reliable anticoagulant effect, not … oral anticoagulation.
Due to the short half-life of the drugs, switching to heparins or other parenteral anticoagulants …

Why is the need for these tests so urgent? Quantification of plasma concentrations of the
DOACs is critical when assessing their potential contribution to serious bleeding, when making …

Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and
provide advantages over existing agents. As with all anticoagulants, management protocols …

… than VKAs include a predictable anticoagulant effect, relatively wide therapeutic window, …
Introduction Direct oral anticoagulants (DOACs) have been licensed in many countries and …

Direct oral anticoagulants (DOACs) inhibit coagulation through factor Xa (apixaban, edoxaban,
rivaroxaban) or thrombin (dabigatran)(Fig. 1), and do not require antithrombin for activity …

… Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K
antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to prevent …

… Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there
are instances when laboratory measurement of the drug anticoagulant effect may be useful. …

… direct oral anticoagulants with traditional vitamin K antagonists, the direct oral anticoagulants
all … In 2008, dabigatran was the first direct oral anticoagulant approved by the European …

… be influenced by anticoagulants and … direct oral anticoagulants (DOACs – dabigatran [DAB],
rivaroxaban [RIV] and apixaban [API]) may also influence LA testing. We tested the effects of …